Strand LS Expands Cancer Profiling Service

May 28, 2015 | Strand Life Sciences announced an expanded StrandAdvantage pan-cancer genomic profiling service. The new version of StrandAdvantage will include a panel that examines 152 genes and pathways known to be impacted by existing targeted solid tumor therapies plus additional chemotherapeutic toxicity and resistance data.

StrandAdvantage was designed to accelerate the analysis of therapeutically-actionable cancer genes and match them to relevant FDA-approved targeted cancer therapies and open clinical trials without the need for multiple tests, the company said in the announcement. The service provides oncologists with clinically actionable results beginning with a report on eight “standard-of-care genes” delivered to the oncologist within eight days. A full report is provided within 15 days that covers all major gene variants and pathways known to be impacted by existing targeted therapies.

“With this expanded panel of genes, StrandAdvantage will provide physicians with even more information about their patients’ solid tumors and help in guiding first-line therapy decisions,” said Scott A. Storrer, global president of Strand Life Sciences in a press release. Press release.